Clinical trial ISRCTN10334895
Status: Recruiting (according to the registry)Phase 2Latest change: Source: ISRCTN (United Kingdom) (via WHO ICTRP)
What's on this page?
This record’s status may be out of date
The trial was registered in August 31, 2018 and still shows as "recruiting" in the registry. Status information in other countries’ registries is often not updated; the trial may have ended or stopped. For current information, check the record itself.
Information in the record
Original title: Cannabidiol for the treatment of patients at a high-risk of psychosis
- Record number
- ISRCTN10334895
- Registry
- ISRCTN (United Kingdom) (via WHO ICTRP)
- Status
- Recruiting (according to the registry)
- Type and phase
- Clinical trial, phase 2
- Participants
- Target: 300
- Condition (as registered)
- Clinical high-risk for psychosis (CHR), Mental and Behavioural Disorders, Clinical high-risk state for psychosis (CHR)
- Countries
- United Kingdom
- Topic in the guide
- Schizophrenia
Timeline
According to the ISRCTN (United Kingdom) (via WHO ICTRP) record. Future dates are the investigator’s estimates and may change.
- Registration: August 31, 2018
History
We check the record once a month via WHO ICTRP; here are the changes we have seen since we started tracking it, newest first.
- : Added to tracking. Status: Recruiting.
Results
All ongoing trials · Schizophrenia: guide page · Thinking of taking part? Which specialist to see